Europe Approves Western Worlds First Stem-cell Therapy For Rare Eye Condition
Biotechnology News
(Reuters) - Europe has approved the Western world's first medicine containing stem cells to treat a rare condition caused by burns to the eye, marking a milestone in the use of the technology. Holoclar, from privately held Italian company Chiesi, was given a marketing green light on Friday by the European Commission for treating so-called limbal stem cell deficiency due to physical or chemical burns. It resembles a contact lens and is made from a biopsy taken from a small undamaged area of a patient's cornea and grown in the laboratory using cell culture. The conditional marketing authorization had been expected, following a positive recommendation by the European Medicines Agency in December.
Source